#cancer research

It will be essential for future research to continue to explore the mechanisms behind these two diseases.

Seaweed-based nanoparticles may offer a way to deliver cancer drugs directly to brain tumors.

Common and cheap epilepsy drug stops tumor growth in mice

An expert hopes to use gathered data to establish guidelines for how best to sample lymph nodes during surgery for pediatric kidney cancer.

American Cancer Society and ACS Cancer Action Network strongly support Monica M. Bertagnolli, MD, as the next NIH director.

Researcher Rachel Lex seeks to understand why certain regions of tissue tend to develop tumors more frequently.

The drug, revumenib, is a menin inhibitor that has led to remission in clinical trials involving acute myeloid leukemia.

Bladder cells’ strategy blocks cancer-causing genetic programs, could be new therapeutic target.

Checkpoint inhibitor therapies are not totally effective at treating relapsed aggressive lymphomas in patients who received CAR T therapy.

The drug, known as NVP-DKY709, boosts the immune response against tumors. A Phase I clinical trial will be completed next year.

The Melanoma Research Alliance looks at the benefits and challenges of a cellular therapy using tumor-infiltrating lymphocytes (TIL).

Damon Runyon researchers look at the metabolism of glioblastomas as a possible route to treatment for this aggressive brain cancer.

The Damon Runyon Cancer Research Foundation highlights exceptional early-career scientists making a difference in cancer research.

To honor a father and uncle lost to skin cancer, owners of racehorse Hot Rod Charlie put part of his winnings toward melanoma research.

Preclinical work identifies better targets and recruits more immune cells to make CAR-T therapy work for solid tumors.

Mutations in the p53 gene contribute to many cancers. A Damon Runyon scientist explores the gene’s ability to suppress pancreatic cancer.